Patients with hypersensitivity to repaglinide or to any of the ingredients of the drug.
Diabetes mellitus type 1, C-peptide negative.
Diabetic ketoacidosis, with or without coma.
Severe hepatic function disorder.
Concomitant use of gemfibrozil.